logo

For the Inventor, By the Inventor

Val-de-marne, France

Fabien J Schweighoffer

This inventor holds 21 USPTO granted patents and 7 published patent applications and 7 EPO patents. Top assignees: Exonhit Therapeutics, Sa, Allergan, Inc., Rhone-Poulenc Rorer S.a.. Active years: 1997-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fabien J Schweighoffer. Retrieved from https://idiyas.com/inventor/fabien-j-schweighoffer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 76.2

 

Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 102(Granted Patents)


Location History:

  • Vincennes, FR (1997 - 2011)
  • Fontenay-sous-Bois, FR (2011)
  • Val-de-marne, FR (2011 - 2016)

Company Filing History:

goldMedal10 out of 25 
 
Exonhit Therapeutics, Sa
 patents
silverMedal7 out of 2,287 
 
Allergan, Inc.
 patents
bronzeMedal4 out of 247 
 
Rhone-Poulenc Rorer S.a.
 patents
4. 2 out of 377 
 
Aventis Pharma S.a.
 patents
where one patent can have more than one assignee

Years Active: 1997-2016

Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents
1. 9303021 - Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds (2016-04-05),
2. 8629165 - Methods for treating cognitive disorders (2014-01-14),
3. 8623891 - Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds (2014-01-07),
4. 8563594 - S1P3 receptor inhibitors for treating pain (2013-10-22),
5. 8173683 - Methods for treating cognitive disorders (2012-05-08),
6. 8003375 - Qualitative differential screening (2011-08-23),
7. 7964191 - Compositions and methods for the treatment of ophthalmic disease (2011-06-21),
8. 7884115 - Methods and compositions for the treatment of pain and other neurological conditions (2011-02-08),
9. 7872015 - Methods involving PDE4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies (2011-01-18),
10. 7514432 - Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis (2009-04-07),
11. 6881571 - Qualitative differential screening (2005-04-19),
12. 6855736 - Molecular target of neurotoxicity (2005-02-15),
13. 6544948 - &Dgr;P62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer (2003-04-08),
14. 6509153 - Genetic markers of toxicity preparation and uses (2003-01-21),
15. 6372432 - Methods and composition for the detection of pathologic events (2002-04-16),

Title: Fabien J Schweighoffer: Innovating Cognitive Disorder Treatments

Introduction: Fabien J Schweighoffer, based in Val-de-Marne, France, is a notable inventor in the field of cognitive disorder treatments. With a remarkable portfolio of 21 patents, his work contributes significantly to advancements in therapeutic methods.

Latest Patents: Schweighoffer's latest patents include innovative methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides and 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides. These patents disclose methods aimed at treating patients suffering from cognitive disorders utilizing specific compounds described in detail within the patent specifications.

Career Highlights: Throughout his career, Fabien Schweighoffer has worked with prestigious companies, including Exonhit Therapeutics and Allergan, Inc. His experience in these organizations underscores his expertise and commitment to developing effective treatments for cognitive disorders.

Collaborations: Schweighoffer has collaborated with esteemed colleagues such as Bruno Tocque and John E Donello, highlighting the teamwork and innovation within his research contributions. These partnerships have facilitated advancements and provided deeper insights into the treatment landscape for cognitive disorders.

Conclusion: Fabien J Schweighoffer's work and patents represent a significant step forward in addressing cognitive disorders. His dedication as an inventor showcases the importance of innovation in the medical field, as he continues to push the boundaries of treatment possibilities.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…